antitumor in Medical Technology

Semafore's SF1126 Exhibits Antitumor and Antiangiogenic Activity

INDIANAPOLIS, Jan. 9 /PRNewswire/ -- Semafore Pharmaceuticals Inc. today announced that a paper published in Cancer Research (2008; Vol. 68, Issue 1: 206-215) reports that SF1126, the company's lead product candidate, exhibits antitumor and antiangiogenic activity. The paper, entitled "A Vas...

Kosan Presents Phase 1 Data Showing Antitumor Activity and Safety Profile of Epothilone KOS-1584 at AACR/NCI/EORTC Meeting

HAYWARD, Calif., Oct. 23 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated (Nasdaq: KOSN ) presented updated data today from a Phase 1 clinical trial showing that KOS-1584/R1645, an epothilone under co-development with Roche, demonstrated antitumor activity and tolerability in patients...

Studies Show Mild Hyperthermia Enhances Antitumor Effects of Alfacell's Onconase

BLOOMFIELD, N.J., March 22, 2007 /PRNewswire-FirstCall/ -- Alfacell Corporation today reported that in vitro studies show mild hyperthermia enhances the therapeutic effects of ONCONASE (ranpirnase), the company's lead investigational drug candidate. In a paper entitled, "Mild hyperthermia predis...

Kosan Presents Preclinical Antitumor and Safety Data On Next-Generation Epothilone KOS-1803 at AACR

HAYWARD, Calif., April 16, 2007 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated today presented preclinical data on KOS-1803, a next-generation epothilone, showing a high level of antitumor activity and a favorable pharmacokinetic and safety profile in a broad range of in vitro tests and ...

EntreMed Presents Multi-Mechanism Antitumor Data for ENMD-1420 in Preclinical Models

Tumor Inhibition Demonstrated in Lung and Colorectal Cancers ROCKVILLE, Md., April 16, 2007 /PRNewswire-FirstCall/ -- EntreMed, Inc. , a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, announced the presentation of results for it...

Abraxis BioScience Presents Results from Pre-Clinical Study That Demonstrates nab-Rapamycin's Robust Antitumor Properties and Ability to Target Intracellular Sites Such as the mTOR Pathway

LOS ANGELES--(BUSINESS WIRE)--Apr 19, 2007 - Abraxis BioScience, Inc. (NASDAQ:ABBI), an integrated, global biopharmaceutical company, presented first-time data from a pre-clinical study evaluating the toxicity and antitumor effect of nab-rapamycin (ABI-009), an albumin-bound mTOR kinase inhibitor, ...

Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO

HAYWARD, Calif., June 04, 2007 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated presented preliminary data from a Phase 2 monotherapy trial showing that tanespimycin demonstrated antitumor activity and tolerability in patients with metastatic melanoma, including one patient with a BRAF mut...

Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO

Tanespimycin TIME Registration Program to Begin Third Quarter 2007 HAYWARD, Calif., June 04, 2007 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated presented data from a dose-escalating Phase 1b clinical trial of its lead Hsp90 inhibitor, tanespimycin (KOS-953) in combination with bortezomi...

Kosan Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Epothilone KOS-1584 at ASCO

HAYWARD, Calif., June 04, 2007 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated presented data from a Phase 1 clinical trial showing that KOS-1584/R1645, an epothilone under co-development with Roche, demonstrated promising antitumor activity and tolerability in patients with solid tumors....

Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO

Clinical Benefit Shown in 35% of HER2-Positive Metastatic Breast Cancer Patients HAYWARD, Calif., June 04, 2007 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated presented data from a Phase 1 clinical trial showing that alvespimycin, its second-generation Hsp90 inhibitor, demonstrated promi...

Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop

PRINCETON, N.J.--(BUSINESS WIRE)--Jun 28, 2007 - Cytogen Corporation (NASDAQ: CYTO) reported updated data from a Phase 1 dose escalation study evaluating QUADRAMET(R) (samarium Sm-153 lexidronam injection) in combination with bortezomib (Velcade(R), Millennium Pharmaceuticals, Inc.) in patients wit...

Oncolytics Biotech(R) Inc. Announces Publication of Research on Synergistic Activity of Reovirus and Chemotherapy in NSCLC

...ished the results of their work examining reovirus and chemotherapy against human non-small cell lung cancer (NSCLC). The paper, entitled "Synergistic antitumor Activity of Oncolytic Reovirus and Chemotherapeutic Agents in Non-Small Cell Lung Cancer Cells" appears online in the July 14, 2009 issue of Molecular...

Afinitor(R) Phase II Data Show Positive Results for Patients With Multiple Types of Lymphoma, Leading to Phase III Trial

... multiple types of cancer," said Alessandro Riva, MD, Executive Vice President, Global Head, Novartis Oncology Development. "These latest data show an antitumor effect in lymphoma that support the rationale for a Phase III study of Afinitor to prevent relapse in patients with diffuse large B-cell lymphoma, whe...

Access Pharmaceuticals Announces Publication of Thiarabine Combination Data

...trating that thiarabine combined with clofarabine provides much greater antitumor activity than achieved by either agent alone. In one colorectal cancer mode...ern Research Institute. The paper is entitled "Enhancement of the in vivo antitumor activity of clofarabine by 1-beta-D-[4-thio-arabinofuranosyl]-cytosine" (...

Neurobiological Technologies' Partner, Celtic Pharma, Announces Results of XERECEPT(R) Phase 3 Clinical Program

...able in this model, as assessed by the laboratory, to results seen with Sutent.(R) These preclinical findings demonstrate that XERECEPT(R) has direct antitumor and angiogenesis inhibition activity, in these models. John Mayo, co-Managing General Partner of Celtic Pharma, said "This product has great s...

Entremed Presents Results of ENMD-2076 Phase 1 Study in Advanced Cancer Patients

...er dose levels evaluated were within the range of where there was excellent antitumor activity in preclinical models. EntreMed Vice President and Chief M...isms of action. Preclinical studies with ENMD-2076 demonstrated significant antitumor activity, including tumor regression, in multiple solid and hematological m...

Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types

...atin(R) LAR Depot Phase III data shows significant antitumor benefit in patients with advanced neuroendocrine t... injectable suspension) demonstrated a significant antitumor effect in patients with metastatic neuroendocrine ...y conducted at 18 sites in Germany to evaluate the antitumor effect of Sandostatin LAR in patients with midgut ...

Ascenta Therapeutics Announces Multiple Presentations on AT-101 at 2009 ASCO Annual Meeting

...ay 30, 8:00 a.m.-12:00 p.m. Min P, et al. Small molecule pan-bcl-2 inhibitor AT-101 induces apoptosis in NSCLC by upregulating noxa and enhances antitumor activity of docetaxel or targeted kinase inhibitors. Abstract #e14591; Publication only. Non-Hodgkin's Lymphoma Kingsley E, et al. An open-...

Karmanos Cancer Institute Researchers Present Breast Cancer Advancements at Conference

...s discovered that when an FDA-approved cancer treatment typically used to treat cutaneous T-cell lymphoma was administered before a novel experimental antitumor agent -- which works best in breast cancers expressing the estrogen receptor (ER) -- estrogen receptors were reinstated in receptor-negative breast ca...

Another LNA-based RNA Inhibitor Enters Clinical Trials

...ceptor (AR) down regulation by locked nucleic acid antisense oligonucleotides specifically inhibits the growth of AR-positive tumor cells" "The antitumor activity of EZN-4150, a potent LNA-based PIK3CA antagonist" "EZN-3042, a novel locked nucleic acid oligonucleotide against survivin, inhibits s...

Compared to Standard Therapies, Pixantrone Decreases Time to Achieve Complete Remission by 47% in Relapsed Aggressive Non-Hodgkin's Lymphoma

...04, and pixantrone has received fast track designation for this indication. About Pixantrone Pixantrone (BBR 2778), a DNA intercalating antitumor agent that contains an aza-anthracenedione molecular structure, differentiating it from anthracycline chemotherapy agents, was discovered by our scien...

Cell Therapeutics and IDIS Announce Agreement for a European Named Patient/Compassionate Use Program for Pixantrone

... in 2004 and pixantrone has received fast track designation for this indication. About Pixantrone Pixantrone (BBR 2778), a DNA intercalating antitumor agent that contains an aza-anthracenedione molecular structure, differentiating it from anthracycline chemotherapy agents, was discovered by our scien...

EntreMed Presents Initial Clinical Results for ENMD-2076

...well tolerated. Data show preliminary evidence of antitumor activity as determined by reduction in tumor marke... Studies demonstrate a substantial dose-dependent antitumor combination effect as assessed by tumor regression. The enhanced antitumor activity observed with the combination of ENMD-207...

Pixantrone Increases Progression-Free Survival by 81% Compared to Standard Chemotherapeutic Agents in Phase III Relapsed Aggressive non-Hodgkin's Lymphoma Trial

...r pixantrone to treat relapsed aggressive NHL in the first quarter of 2009. About Pixantrone Pixantrone (BBR 2778), a DNA intercalating antitumor agent that contains an aza-anthracenedione molecular structure, differentiating it from anthracycline chemotherapy agents, was discovered by our scien...

Pixantrone Pre-NDA Communication from FDA Provides Cell Therapeutics Basis to Begin Rolling NDA Submission

...004 and pixantrone has received fast track designation for this indication. About Pixantrone Pixantrone (BBR 2778), a DNA intercalating antitumor agent that contains an aza-anthracenedione molecular structure, differentiating it from anthracycline chemotherapy agents, was discovered by our scien...

New Study First to Confirm Sandostatin LAR(R) Depot Controls Tumor Growth in Patients With Rare Gastrointestinal Tumors

...ide acetate suspension for injection) demonstrated antitumor benefit in patients with metastatic neuroendocrine...idence has suggested that Sandostatin LAR provides antitumor effects, but these are the first data to confirm t...y conducted at 18 sites in Germany to evaluate the antitumor effect of Sandostatin LAR in patients with NETs. T...

Cell Therapeutics' Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint

... am Eastern time and a webcast will be available at http://www.celltherapeutics.com . About Pixantrone Pixantrone (BBR 2778), a DNA intercalating antitumor agent that contains an aza-anthracenedione molecular structure, differentiating it from anthracycline chemotherapy agents, was discovered by our scien...

Cell Therapeutics Announces Study Data Set Cut-off for Phase III Pivotal Pixantrone (301) Trial

...stration (FDA) and pixantrone has received fast track designation for this indication. About Pixantrone Pixantrone (BBR 2778), a DNA intercalating antitumor agent that contains an aza-anthracenedione molecular structure, differentiating it from anthracycline chemotherapy agents, was discovered by our scien...

Millennium Presents New Data on Investigational Drugs for Novel Cancer Targets at EORTC-NCI-AACR Symposium

...nd Development, Westmont, Illinois -- Abstract #78: Poster -- In vivo antitumor efficacy of TAK-285, a novel ErbB1/ErbB2 dual kinase inhibitor -- L... Development, Westmont, Illinois -- Abstract #313: Poster -- Combined antitumor efficacies of TAK-285, a novel ErbB1/ErbB2 dual kinase inhibitor, with ...

Pharmaleads' Lead Candidate for Pain, PL37, Enters Phase I

...valence in the world's population of up to 6%, according to the most recent surveys, with many causes such as shingles, herpes, diabetes, antiviral or antitumor chemotherapy surgery, or low back disorders. Neuropathic pain does not respond well to usual painkillers. Worldwide market for neuropathic pain is est...

SF1126, Semafore's PI3 Kinase Inhibitor, Found to Block Angiogenic Signaling From Both VEGF and Bv8 in Multiple Cell Lines

...ells). Inhibiting Bv8 with antibodies has also been shown by others to have antitumor effects in mouse xenograft models. "SF1126 could have additional impact i...d PLK-1. This adds another layer of versatility to what SF1126 can do as an antitumor agent." About Semafore Semafore is a clinical stage drug discovery and ...

Aegera Initiates a Fifth Phase 1 and 2 Clinical Trial for AEG35156

...EG35156," stated Dr. Jacques Jolivet, Aegera's VP Clinical. "This clinical trial will specifically study the role played by XIAP knockdown in inducing antitumor activity in CLL, SLL and FL." "Our clinical program around AEG35156 continues to expand and broaden as we seek to move this therapeutic forward to a...

FDA Lifts Clinical Hold on Genta's Tesetaxel, a Leading Oral Taxane

...ood counts) and peripheral neuropathy (disabling nerve damage). With administration as an oral capsule, tesetaxel was developed to maintain the high antitumor activity of the taxane drug class while eliminating infusion reactions, reducing neuropathy, and increasing patient convenience. The oral route also e...

Semafore Pharmaceuticals Reports Positive Interim Results from a Phase I Study of SF1126, a Targeted Pan-PI3K Inhibitor, in Patients with Advanced Solid Tumors

...ty data and early signals of activity seen with SF1126," said Dennis McKeever, Semafore Pharmaceuticals' CEO. "We believe that SF1126's dual action of antitumor and antiangiogenic activity represents a step forward in delivering new therapies to cancer patients." About SF1126 SF1126 is a small-molecule con...

Kosan's Lead Hsp90 Inhibitor, Tanespimycin, Shows High Level of Activity in Trastuzumab Resistant/Refractory HER2-Positive Breast Cancer in a Phase 2 Trial

...d that its lead Hsp90 inhibitor, tanespimycin, demonstrated a high level of antitumor activity in a Phase 2 trial when administered in combination with trastuzum...ase) -- 5 patients or 19% had SD of 4 or more cycles (4 week cycle) antitumor activity and toxicity were similar between the Injection and Injectable Sus...

EntreMed Presents MKC-1 Phase 2 Data at American Society of Clinical Oncology Annual Meeting

... antitumor Activity Demonstrated in Metastatic Breast Cancer ...for tumor response. Of the evaluable patients, the antitumor activity observed with MKC-1 included 3 patients w...evious studies with MKC-1 demonstrate broad-acting antitumor effects, showing tumor growth inhibition or regres...

Anti-TGF-Beta Antisense AP 12009 Shows Very Good Safety and Tolerability in Systemic Treatment of Pancreatic Carcinoma, Malignant Melanoma and Colorectal Carcinoma

...dy objective is to determine the maximum tolerated dose (MTD). Further objectives include assessment of safety and tolerability, pharmacocinetics, and antitumor activity of AP 12009. An update of this ongoing study will be presented at the meeting. AP 12009 and TGF-beta 2 AP 12009 is an antisense drug - a ...

Early Data Presented at ASCO Show Potential of RAD001 to Enhance Efficacy of, and Overcome Resistance to, Breast Cancer Treatments

... mediates trastuzumab resistance and has the potential to help restore response in patients who are refractory to therapy. RAD001 works through direct antitumor activity as well as through its influence on two of the most important pathways for breast cancer, the estrogen receptor and the HER2/neu pathways. ...

Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer

...he American Society of Clinical Oncology (ASCO) in Chicago, Illinois, USA. "This study is the first large-scale trial to demonstrate the significant antitumor benefit of zoledronic acid," said lead investigator Michael Gnant, M.D., of the Medical University of Vienna. "These new findings may allow oncologist...

New Data Show TORISEL Improves Progression-Free Survival for Patients With Relapsed/Refractory Mantle Cell Lymphoma

... progression-free survival for these patients," says Georg Hess, M.D., Johannes Gutenberg-Universitat, Mainz, Germany. "These data further support the antitumor activity seen in phase 2 studies of temsirolimus in relapsed/refractory mantle cell lymphoma and indicate that mTOR inhibition may be a viable approac...